Semaglutide vs Dulaglutide on Epicardial Adipose Tissue

University of Miami

Status

Completed

Conditions

Epicardial Fat

Study type

Observational

Funder types

Other

Identifiers

NCT04200625

20190944

Details and patient eligibility

About

Epicardial Fat (EAT), the visceral fat depot of the heart, is a modifiable cardio-metabolic risk factor and therapeutic target. EAT expresses GLP-1 receptors (GLP-1R). GLP-1 receptor agonist liraglutide is known to significantly decrease EAT thickness. However, the effects of GLP-1 receptor agonists semaglutide and dulaglutide on EAT thickness are unknown

Full description

This is a retrospective, observational, case control study. Data were obtained from retrospective review of the electronic medical records.

Patients were treated with either semaglutide, dulaglutide or metformin as standard of care, during routine clinical practice, regardless of the study. Each patient underwent routine labs and an onsite ultrasound measurement of EAT thickness at baseline and at the routine 12-week follow up visit, as standard of care.

Enrollment

80 patients

Sex

All

Ages

18 to 90 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Type 2 diabetes,
BMI ≥27 kg/m2,
Age ≥ 18 years old

Exclusion criteria

Type 1 diabetes
Concurrent use of dipeptidyl peptidase 4 (DPP-4) inhibitors or other GLP-1 agonist receptors
History of diabetic ketoacidosis
Known contraindications to GLP-1 receptor agonists such as previous history of pancreatitis or medullary thyroid carcinoma, personal or family history of multiple endocrine neoplasia type 2
Acute infective diseases, cancer or chemotherapy
Use of systemic corticosteroids within the 3 months prior this study
Known or suspected allergy to semaglutide or dulaglutide excipients or related products
Pregnancy, breastfeeding or the intention of becoming pregnant